ICR and Royal Marsden NHS Foundation Trust open new integrated pathology unit

2023-05-12
Pharmaceutical Technology
临床研究
ICR and Royal Marsden NHS Foundation Trust open new integrated pathology unit
Preview
来源: Pharmaceutical Technology
A cancer sample pathology slide showing computerised data points. Credit: ICR/Royal Marsden IPU.
The Institute of Cancer Research (ICR)Cancer Research (ICR), along with its hospital partner The Royal Marsden NHS Foundation Trust, has opened a new joint integrated pathology unit (IPU).
The IPU is the first centre of its kind in England and aims to enhance cancer diagnosis and treatment by integrating digital imaging with artificial intelligence (AI).
Recommended Reports
ICR and Royal Marsden NHS Foundation Trust open new integrated pathology unit
Preview
来源: Pharmaceutical Technology
ReportsGlobal Mergers and Acquisitions (M&A) Deals in the Healthcare Sector, Q2 2021 - Top Themes - ... GlobalData
ICR and Royal Marsden NHS Foundation Trust open new integrated pathology unit
Preview
来源: Pharmaceutical Technology
ReportsInnovation in Healthcare: Ct-Angiography Image Acquisition System GlobalData
View all
The IPU will support clinical trial research and will employ new technology to diagnose cancer in a faster and less expensive way.
It has received funding from The Royal Marsden Cancer Charity, the Institute of Cancer Research (ICR)Cancer Research (ICR) and the National Institute for Health and Care Research, (NIHR) Royal Marsden and ICR Biomedical Research Centre (BRC).
Situated at the NIHR’s centre for molecular pathology in Sutton, London, the IPU will enable pathologists to conduct new research as well as enhance cancer diagnosis and treatment for patients at The Royal Marsden and other cancer treatment sites.
Pathologists at the unit are already digitising tissue samples derived from patients admitted to the Royal Marsden or patients participating at clinical trials in other cancer centres across the UK.
They have also created tissue research images at the IPU and other ICR research laboratories.
Researchers at the unit are integrating digital pathology, tissue hybridisation and AI technologies to gain better understanding of major aspects of cancer pathology.
The researchers also aim to develop technologies which provide insights into how cancers interact with their environment as they develop and grow.
These could also help diagnose patients more accurately.
The Institute of Cancer Research London’s chief executive Kristian Helin stated: “Digital pathology is set to hand scientists and clinicians a whole new set of tools to understand, diagnose, and treat cancer.
“Thanks to our close partnership with The Royal Marsden, we have a special opportunity to collect data, use them for our research and create new diagnostic technologies and treatments that can hopefully directly benefit cancer patients.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。